Acute Coronary Syndromes

Acute coronary syndrome (ACS) is most commonly caused by a heart attack (myocardial infarction) where blood flow to the heart is suddenly blocked. This is usually caused by a blood clot from a ruptured coronary artery atherosclerotic plaque. Other causes include spontaneous coronary artery dissection (SCAD), which most commonly occurs in women. ACS is usually treated in a cath lab with angioplasty and the placement of a stent to prop the vessel open.

Colchicine Lodoco Agepha Pharma price cost cardiovascular disease CVD

What will Lodoco cost? Looking ahead after FDA’s historic approval of colchicine for CVD

Our pricing strategy for Lodoco is focused on helping to ensure access to as many people as possible, an executive with Agepha Pharma told Cardiovascular Business. 

June 27, 2023
The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment. Colchicine prevents coronary artery plaque inflammation, heart inflammation. Colchicine for coronary artery disease. Colchicine for coronary inflammation FDA Approves Colchicine for Decreasing CV Events FDA Approves Colchicine for decreasing inflammation caused by coronary atherosclerosis.

Cardiologists applaud FDA’s approval of colchicine for CVD

"The FDA's approval of colchicine confirms that we are entering a new era of patient care," said one veteran cardiologist familiar with the drug. 

June 26, 2023
The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment. Colchicine prevents coronary artery plaque inflammation, heart inflammation. Colchicine for coronary artery disease. Colchicine for coronary inflammation FDA Approves Colchicine for Decreasing CV Events FDA Approves Colchicine for decreasing inflammation caused by coronary atherosclerosis.

FDA approves colchicine, the first anti-inflammatory drug for treating cardiovascular disease

The FDA's approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes.

June 20, 2023
Money dollar investments

Bitterroot Bio, a new biotech company launched by physicians and industry veterans, raises $145M

The new company formed in 2021, but waited until now to publicly launch. Its founders included two Stanford University physicians.

June 8, 2023
Recall | Product recall

FDA announces recall of certain Impella heart pumps after 3 patient injuries, nearly 200 complaints

The FDA has labeled this as a Class I recall, which means using these devices can lead to significant injuries, including death.

June 5, 2023
Regularly eating avocados is associated with a reduced risk of cardiovascular disease, according to a new study.

Plant-based diets—both vegetarian and vegan—linked to lower cholesterol levels, reduced risk of blocked arteries

A new systematic review and meta-analysis of 30 RCTs highlighted numerous benefits associated with vegetarian and vegan diets. Combining a plant-based diet with statin therapy, one researcher noted, could result "in an even larger beneficial effect.”

May 25, 2023
A CTA scan being performed at Beaumont Hospital in Michigan by cardiac CT expert Kavitha M Chinnaiyan, MD. CCTA has largely been used at academic medical centers for the past decade, but it is now expanding in 2022 to community hospitals and clinics thanks to a Class 1A recommendation in the 2021 chest pain guidelines. #CCTA #CTA #Beaumont

Imaging results more helpful than genetics when predicting heart disease, new head-to-head study confirms

The new analysis, published in JAMA, suggests that CT results can help identify medium- and high-risk patients who may need to be considered for statin therapy or other preventive treatments.

May 23, 2023
The World Health Organization has published a new guideline recommending against the use of artificial sweeteners such as aspartame and sucralose to lose weight or reduce the risk of noncommunicable diseases.

WHO warns against use of artificial sweeteners, highlighting CVD and diabetes risks

The World Health Organization has published a new guideline recommending against the use of artificial sweeteners such as aspartame and sucralose to lose weight or reduce the risk of noncommunicable diseases.

May 16, 2023

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Trimed Popup
Trimed Popup